OreStocks

Sage Potash Corp. press release

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

TSXV - TSX Venture Exchange · Potash · Lithium · Bromine · Boron · Canada

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash payable upon achieving certain net sales and commercial milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( lewis.kahn@ksfcounsel.com ) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-sage/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

CONNECT WITH US: FaceBook || Instagram || YouTube || TikTok || LinkedIn

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618150169/en/

Kahn Swick & Foti, LLC Lewis S. Kahn lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163

Earlier from Sage Potash Corp.